ID: ALA3586090

Max Phase: Preclinical

Molecular Formula: C17H20F3N5S2

Molecular Weight: 415.51

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC1(C)CN=C(N2CCN(c3ncnc4sc(CC(F)(F)F)cc34)CC2)S1

Standard InChI:  InChI=1S/C17H20F3N5S2/c1-16(2)9-21-15(27-16)25-5-3-24(4-6-25)13-12-7-11(8-17(18,19)20)26-14(12)23-10-22-13/h7,10H,3-6,8-9H2,1-2H3

Standard InChI Key:  SFDROHXKTATJBI-UHFFFAOYSA-N

Associated Targets(Human)

MV4-11 (7307 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MEN1 Tchem Menin/Histone-lysine N-methyltransferase MLL (48157 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MEN1 Tchem Menin (447 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDM1A Tchem Lysine-specific histone demethylase 1 (3916 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAOB Tclin Monoamine oxidase B (8835 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 415.51Molecular Weight (Monoisotopic): 415.1112AlogP: 3.80#Rotatable Bonds: 2
Polar Surface Area: 44.62Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.08CX LogP: 4.32CX LogD: 4.30
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.75Np Likeness Score: -1.44

References

1. Senter T, Gogliotti RD, Han C, Locuson CW, Morrison R, Daniels JS, Cierpicki T, Grembecka J, Lindsley CW, Stauffer SR..  (2015)  Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility.,  25  (13): [PMID:25987377] [10.1016/j.bmcl.2015.04.026]
2. Pollock J, Borkin D, Lund G, Purohit T, Dyguda-Kazimierowicz E, Grembecka J, Cierpicki T..  (2015)  Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes.,  58  (18): [PMID:26288158] [10.1021/acs.jmedchem.5b00975]
3. Chen QB, Gao J, Zou GA, Xin XL, Aisa HA..  (2018)  Piperidine Alkaloids with Diverse Skeletons from Anacyclus pyrethrum.,  81  (6): [PMID:29775308] [10.1021/acs.jnatprod.8b00239]
4. Jedwabny W, Kłossowski S, Purohit T, Cierpicki T, Grembecka J, Dyguda-Kazimierowicz E..  (2017)  Theoretical models of inhibitory activity for inhibitors of protein-protein interactions: targeting menin-mixed lineage leukemia with small molecules.,  (12): [PMID:29456828] [10.1039/C7MD00170C]
5. Wang X, Su M, Li Y, Liu T, Wang Y, Chen Y, Tang L, He YP, Ding X, Yu F, Shen J, Li J, Zhou Y, Chen YL, Xiong B..  (2019)  Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.,  29  (6): [PMID:30713023] [10.1016/j.bmcl.2019.01.017]
6. Ren J, Xu W, Tang L, Su M, Chen D, Chen YL, Zang Y, Li J, Shen J, Zhou Y, Xiong B..  (2016)  Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface.,  26  (18): [PMID:27528435] [10.1016/j.bmcl.2016.07.074]

Source